A Year After Collaborating with Gilead, Cartography Biosciences Maps Out its Own Phase 1 with $67M Series B

Cartography Biosciences raised $67M in a Series B round led by Pfizer and Amgen’s venture arms to advance its bispecific and multispecific antibody therapies for cancer. The company plans to begin its first clinical trial early next year, testing its T cell engager CBI-1214, which targets the LY6G6D antigen in colorectal cancer patients.